APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted Drugs for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Targeted Drugs for Multiple Sclerosis Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchTargeted Drugs for Multiple Sclerosis Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted Drugs for Multiple Sclerosis Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Targeted Drugs for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted Drugs for Multiple Sclerosis Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted Drugs for Multiple Sclerosis Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Targeted Drugs for Multiple Sclerosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Targeted Drugs for Multiple Sclerosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Targeted Drugs for Multiple Sclerosis market include NOVARTIS, Roche, Biogen, Sanofi, Janssen and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Targeted Drugs for Multiple Sclerosis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeted Drugs for Multiple Sclerosis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeted Drugs for Multiple Sclerosis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Targeted Drugs for Multiple Sclerosis market.

Targeted Drugs for Multiple Sclerosis Segment by Company

NOVARTIS

Roche

Biogen

Sanofi

Janssen

Bristol-Myers Squibb

Targeted Drugs for Multiple Sclerosis Segment by Type

Oral

Injection

Targeted Drugs for Multiple Sclerosis Segment by Application

Hospital

Clinic

Other

Targeted Drugs for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Targeted Drugs for Multiple Sclerosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Targeted Drugs for Multiple Sclerosis key companies, revenue, market share, and recent developments.

3. To split the Targeted Drugs for Multiple Sclerosis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Targeted Drugs for Multiple Sclerosis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeted Drugs for Multiple Sclerosis significant trends, drivers, influence factors in global and regions.

6. To analyze Targeted Drugs for Multiple Sclerosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted Drugs for Multiple Sclerosis industry.

Chapter 3: Detailed analysis of Targeted Drugs for Multiple Sclerosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Targeted Drugs for Multiple Sclerosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Targeted Drugs for Multiple Sclerosis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeted Drugs for Multiple Sclerosis Industry Trends Table 2. Targeted Drugs for Multiple Sclerosis Industry Drivers Table 3. Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges Table 4. Targeted Drugs for Multiple Sclerosis Industry Restraints Table 5. Global Targeted Drugs for Multiple Sclerosis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeted Drugs for Multiple Sclerosis Revenue Share by Company (2021-2026) Table 7. Global Targeted Drugs for Multiple Sclerosis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Targeted Drugs for Multiple Sclerosis Key Company Manufacturing Base & Headquarters Table 9. Global Targeted Drugs for Multiple Sclerosis Company, Product Type & Application Table 10. Global Targeted Drugs for Multiple Sclerosis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Targeted Drugs for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Targeted Drugs for Multiple Sclerosis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Targeted Drugs for Multiple Sclerosis Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Targeted Drugs for Multiple Sclerosis Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Type (2021-2026) Table 20. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Targeted Drugs for Multiple Sclerosis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Targeted Drugs for Multiple Sclerosis Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Targeted Drugs for Multiple Sclerosis Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Application (2021-2026) Table 28. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Application (2027-2032) Table 29. Global Targeted Drugs for Multiple Sclerosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Targeted Drugs for Multiple Sclerosis Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Region (2021-2026) Table 32. Global Targeted Drugs for Multiple Sclerosis Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Region (2027-2032) Table 34. Global Targeted Drugs for Multiple Sclerosis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Targeted Drugs for Multiple Sclerosis Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Targeted Drugs for Multiple Sclerosis Sales Value Market Share by Country (2021-2026) Table 37. Global Targeted Drugs for Multiple Sclerosis Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Targeted Drugs for Multiple Sclerosis Sales Value Market Share by Country (2027-2032) Table 39. NOVARTIS Company Information Table 40. NOVARTIS Business Overview Table 41. NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio Table 43. NOVARTIS Recent Development Table 44. Roche Company Information Table 45. Roche Business Overview Table 46. Roche Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Roche Targeted Drugs for Multiple Sclerosis Product Portfolio Table 48. Roche Recent Development Table 49. Biogen Company Information Table 50. Biogen Business Overview Table 51. Biogen Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio Table 53. Biogen Recent Development Table 54. Sanofi Company Information Table 55. Sanofi Business Overview Table 56. Sanofi Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio Table 58. Sanofi Recent Development Table 59. Janssen Company Information Table 60. Janssen Business Overview Table 61. Janssen Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio Table 63. Janssen Recent Development Table 64. Bristol-Myers Squibb Company Information Table 65. Bristol-Myers Squibb Business Overview Table 66. Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio Table 68. Bristol-Myers Squibb Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. Targeted Drugs for Multiple Sclerosis Product Image Figure 2. Global Targeted Drugs for Multiple Sclerosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted Drugs for Multiple Sclerosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeted Drugs for Multiple Sclerosis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Targeted Drugs for Multiple Sclerosis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Targeted Drugs for Multiple Sclerosis Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Targeted Drugs for Multiple Sclerosis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Targeted Drugs for Multiple Sclerosis Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Application (2021-2032) Figure 18. Global Targeted Drugs for Multiple Sclerosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 21. North America Targeted Drugs for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Targeted Drugs for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Targeted Drugs for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 27. South America Targeted Drugs for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Targeted Drugs for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • NOVARTIS
  • Roche
  • Biogen
  • Sanofi
  • Janssen
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeted Drugs for Multiple Sclerosis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Targeted Drugs for Multiple Sclerosis Market Dynamics
  1. 2.1 Targeted Drugs for Multiple Sclerosis Industry Trends
  2. 2.2 Targeted Drugs for Multiple Sclerosis Industry Drivers
  3. 2.3 Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Targeted Drugs for Multiple Sclerosis Industry Restraints
3 Targeted Drugs for Multiple Sclerosis Market by Company
  1. 3.1 Global Targeted Drugs for Multiple Sclerosis Company Revenue Ranking in 2025
  2. 3.2 Global Targeted Drugs for Multiple Sclerosis Revenue by Company (2021-2026)
  3. 3.3 Global Targeted Drugs for Multiple Sclerosis Company Ranking (2024-2026)
  4. 3.4 Global Targeted Drugs for Multiple Sclerosis Company Manufacturing Base and Headquarters
  5. 3.5 Global Targeted Drugs for Multiple Sclerosis Company Product Type and Application
  6. 3.6 Global Targeted Drugs for Multiple Sclerosis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Targeted Drugs for Multiple Sclerosis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Targeted Drugs for Multiple Sclerosis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Targeted Drugs for Multiple Sclerosis Market by Type
  1. 4.1 Targeted Drugs for Multiple Sclerosis Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Type
  5. 4.2.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Type (2021-2032)
  7. 4.2.3 Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Type (2021-2032)
5 Targeted Drugs for Multiple Sclerosis Market by Application
  1. 5.1 Targeted Drugs for Multiple Sclerosis Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Application
  6. 5.2.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Application (2021-2032)
  8. 5.2.3 Global Targeted Drugs for Multiple Sclerosis Sales Value Share by Application (2021-2032)
6 Targeted Drugs for Multiple Sclerosis Regional Value Analysis
  1. 6.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032)
  7. 6.3.2 North America Targeted Drugs for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032)
  10. 6.4.2 Europe Targeted Drugs for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Targeted Drugs for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032)
  16. 6.6.2 South America Targeted Drugs for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Targeted Drugs for Multiple Sclerosis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Targeted Drugs for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
7 Targeted Drugs for Multiple Sclerosis Country-level Value Analysis
  1. 7.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Targeted Drugs for Multiple Sclerosis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Targeted Drugs for Multiple Sclerosis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Targeted Drugs for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Targeted Drugs for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Targeted Drugs for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 NOVARTIS
  2. 8.1.1 NOVARTIS Company Information
  3. 8.1.2 NOVARTIS Business Overview
  4. 8.1.3 NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio
  6. 8.1.5 NOVARTIS Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Targeted Drugs for Multiple Sclerosis Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio
  18. 8.3.5 Biogen Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Janssen
  26. 8.5.1 Janssen Company Information
  27. 8.5.2 Janssen Business Overview
  28. 8.5.3 Janssen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio
  30. 8.5.5 Janssen Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst